期刊文献+

载顺铂超顺磁γ-Fe2O3纳米粒子的制备与表征 被引量:3

Preparation and characterization of cisplatin-loaded super paramagnetic gamma-Fe_2O_3 nanoparticles
下载PDF
导出
摘要 背景:将化疗药物联接在磁性纳米载体上,在外加磁场的引导下使所载药物定向集中于靶向治疗部位,在增强疗效同时还可降低毒性不良反应。目的:制备海藻酸钠改性的磁性纳米粒子及其负载顺铂药物,分析产物的磁学性质。方法:通过Fe2+在乙醇胺水溶液中一步合成磁性纳米粒子,用海藻酸钠作偶联剂使磁性纳米粒子与顺铂相连,制备磁性纳米粒子药物。结果与结论:X射线衍射花样证明产物为γ-Fe2O3纯相,透射电子显微镜表明磁性纳米粒子直径平均约10nm,载顺铂后药物包覆于纳米粒子周围,磁化曲线显示纳米粒子为超顺磁性,核磁共振得到纳米粒子的弛豫率为0.11602mmol/ms。表明所制备磁性纳米粒子及其载顺铂超顺磁性纳米粒子药物性质稳定,具有作为磁性纳米粒子药物的特性。 BACKGROUND:Induced by external magnetic field,the chemotherapy drug loaded on magnetic nanocarrier can be directly collected on target therapy area,which will enhance the curative effect and reduce the toxicity and adverse reaction.OBJECTIVE:To prepare sodium alginate-modified magnetic nanoparticles and cisplatin-loaded magnetic nanoparticle medicine,and to study the magnetic properties of the products.METHODS:One-step reaction by the hydrolysis of Fe2+ in the aqueous solution of ethanolamine was employed for the preparation of magnetic nanoparticles.Sodium alginate was used as coupling agent to prepare magnetic nanoparticle medicine making magnetic nanoparticles and cisplatin interconnected.RESULTS AND CONCLUSION:X-ray diffraction patterns proved that the product was pure γ-Fe2O3 phase.Transmission electron microscope images indicated that the average diameter of magnetic nanoparticles was about 10 nm,which were coated by cisplatin.Super paramagnetic behavior could be detected in the magnetization curve.A relaxation rate of 0.116 02 mmol/ms was obtained by nuclear magnetic resonance.The as-prepared magnetic nanoparticles and the cisplatin-loaded magnetic nanoparticle medicine showed a good stability,the physical properties of which revealed that it had the potential characteristics as magnetic nanoparticle targeted medicine.
出处 《中国组织工程研究》 CAS CSCD 2012年第12期2137-2140,共4页 Chinese Journal of Tissue Engineering Research
基金 江西省科技厅资助项目(2008BA04400)~~
  • 相关文献

参考文献21

  • 1Rosenberg B,Van Camp L,Kirgan T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode[J].Nature,1965.698-699.
  • 2Pinto AL,Lippard SJ. Binding of the antitumor drug cisdiamminedichloroplatinum(II) (cisplatin) to DNA[J].Biochimica Et Biophysica Acta,1985.167-180.
  • 3Lepre CA,Lippard SJ. Interaction of platinum antitumor compounds with DNA[J].Nucleic Acids and Molecular Biology,1990.3-9.
  • 4Sasaki H,Niimi S,Akiyama M. Antiumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo[J].Cancer Research,1999.3919-3922.
  • 5Shulman TP,Gibson D,Cohen R. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance[J].Biochimica Et Biophysica Acta,2001.278-291.
  • 6Zhang JS,Imai T,Suenaga A. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexs prepared with chondroitin sulfate A and C[J].International Journal of Pharmaceutics,2002.23-31.
  • 7Savic R,Luo L,Eisenberg A. Micellar nanocontainers distribute to defined cytoplasmic organelles[J].Science,2003,(5619):615-618.doi:10.1126/science.1078192.
  • 8Avichezer D,Schechter B,Armon R. Functional polymers in drug delivery:carrier-supported CDDP (cis-platin) complexs of polycarboxylates-effect on human ovarian carcinoma[J].Reactive and Functional Polymers,1998.59-69.
  • 9Alexiou C,Jurgons R,Schmid RJ. Magnetic drug targeting -biodistribution of the magnetic carrier and the chemotherapeutic agent mixtoxantrone after locoregional cancer treatment[J].Journal of Drug Targeting,2003.139-149.
  • 10Arias JL,Reddy LH,Othman M. Squalene based nanocomposites:a new platform for the design of multifunctional pharmaceutical theragnostics[J].ACS Nano,2011.1513-1521.

同被引文献66

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部